Drug-induced myopathies in man

Area of Science:

• Neurology
• Pharmacology
• Internal Medicine

Background:

• Drug-induced diseases account for a significant percentage of hospital admissions, potentially underestimating total drug-related morbidity.
• Skeletal muscle, comprising 45% of body weight and playing a vital metabolic role, is susceptible to drug-induced effects.
• Understanding drug impacts on the neuromuscular system is increasingly vital due to expanding therapeutic options.

Purpose of the Study:

• To review the main drug-induced neuromuscular syndromes.
• To highlight the importance of recognizing and managing drug-induced myopathies.
• To differentiate myopathies from drug-induced neuropathies, while acknowledging potential overlap.

Main Methods:

• Review of existing literature on drug-induced myopathies and neuropathies.
• Summarization of key features of major drug-induced neuromuscular syndromes.
• Inclusion of specific examples of drug effects in conditions like myasthenia gravis and spasticity.

Main Results:

• Drug-induced myopathies, while less common than other drug toxicities, may be underdiagnosed.
• Milder forms of myopathy could be more prevalent due to the large mass and metabolic function of skeletal muscle.
• Some drugs can induce both myopathic and neuropathic conditions.

Conclusions:

• Early recognition and discontinuation of offending agents are critical for managing drug-induced myopathies.
• Drug-induced neuromuscular syndromes, if untreated, can progress from reversible conditions to severe outcomes.
• Awareness of drug effects on the neuromuscular system is essential for clinicians managing diverse patient populations.